Engineering AAV capsids for enhanced transduction of skeletal muscle

工程化 AAV 衣壳以增强骨骼肌的转导

• 批准号: 10576418
• 负责人: MICHAEL DAVID ALPERT
• 金额: $ 101.22万
• 依托单位: EMMUNE, INC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10576418
• 关键词: Adjuvant; Aducanumab; Alzheimer' s Disease; Animals; Antibodies; Antibody Response; Biological; Biological Products; Blood Glucose; Capsid; Capsid Proteins; Cardiovascular Diseases; Cell Culture Techniques; Clinical; Clinical Trials; Dangerousness; Dependovirus; Detection; Disease; Dose; Duchenne muscular dystrophy; Engineering; Enzyme-Linked Immunosorbent Assay; Factor IX; Fasting; Gene Delivery; Gene Transduction Agent; Genetic; Goals; Grant; HIV; Human; Immune response; In Vitro; Injections; Insulin; Insulin Receptor; Intramuscular; Luciferases; Mediating; Modeling; Modification; Monitor; Monoclonal Antibodies; Mus; Muscle; Muscle Fibers; Patients; Pattern; Pharmaceutical Preparations; Phase II Clinical Trials; Protein Secretion; Protocols documentation; Recombinant adeno-associated virus (rAAV); Risk; Rodent; Safety; Serum; Serum Proteins; Site; Skeletal Muscle; Stains; Testing; Therapeutic; Therapeutic Agents; Time; Tissue Sample; Tissues; Transgenes; Translating; Tropism; Variant; Virus Inhibitors; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; bioluminescence imaging; blood glucose regulation; cellular transduction; clinically relevant; design; experimental study; frontier; gene product; gene therapy; immunogenic; immunoreaction; improved; inhibitor; intravenous administration; lipoprotein lipase; mini-dystrophin; neutralizing antibody; nonhuman primate; peptidomimetics; phase I trial; pre-clinical; prototype; receptor binding; safety assessment; success; therapeutic target; therapeutic transgene; transduction efficiency; transgene expression; vector

ABSTRACT We are developing an improved adeno-associated virus (AAV)-based gene therapy vector that we call “enhanced AAV” or “eAAV” for short. eAAV is specifically designed for gene delivery to skeletal muscle tissue. Based on preliminary studies in mice we expect it will be approximately 100 times more effective than the recombinant AAVs (rAAV1 and rAAV8) used in recent clinical trials. This gain in efficiency should allow us to achieve far higher levels of therapeutic transgene products, either directly, due to increased transduction efficiency, or indirectly, by allowing us to use less vector and thereby reduce the likelihood of host immune responses to the transgene product. The aims of this grant are threefold. Aim 1 is to finalize the design of the eAAV product in cell culture and rodent studies. Aim 2 is to test the final eAAV product in nonhuman primates, and Aim 3 is to determine whether or not it poses any unique safety risks compared to other rAAV vectors. Aim 2 comprises the bulk of the project. Here we will compare eAAV to rAAV for its ability to express both alpha-1 antitrypsin (AAT) and the human immunodeficiency virus (HIV)-inhibitor eCD4 from skeletal muscle. Achieving therapeutic levels of AAT would allow for a permanent cure of genetic AAT-deficiency while achieving reliably high levels of eCD4 expression would enable a one-shot, potentially life-long treatment for HIV.

摘要